Phase II adaptive SBRT + defactinib (FAK) + avutometinib (RAF/MEK clamp) in advanced PDAC

Washington University and Verastem Oncology explore stromal and MAPK co-targeting wrapped around adaptive SBRT, with a safety lead-in. Unresectable PDAC still leans on FOLFIRINOX or gem/nab-paclitaxel with modest PFS; FAK inhibition may loosen desmoplastic barriers while MEK/RAF modulation hits KRAS-driven signaling—potentially boosting both local control and systemic disease stability. Primary DLTs/PFS and R0 resection rates (where applicable) will be telling.